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Validation of analytical methodology for quantification of cefazolin 
sodium pharmaceutical dosage form by high performance liquid 
chromatography to be applied for quality control in pharmaceutical 
industry
Tahisa Marcela Pedroso*, Hérida Regina Nunes Salgado
Department of Drugs and Pharmaceuticals, School of Pharmaceutical Sciences,  
University of the State of São Paulo “Júlio de Mesquita Filho”, Araraquara, SP, Brazil
A reversed-phase high performance liquid chromatography method was validated for the determination 
of cefazolin sodium in lyophilized powder for solution for injection to be applied for quality control in 
pharmaceutical industry. The liquid chromatography method was conducted on a Zorbax Eclipse Plus C18 
column (250 x 4.6 mm, 5 μm), maintained at room temperature. The mobile phase consisted of purified 
water: acetonitrile (60: 40 v/v), adjusted to pH 8 with triethylamine. The flow rate was of 0.5 mL min-1 
and effluents were monitored at 270 nm. The retention time for cefazolin sodium was 3.6 min. The 
method proved to be linear (r2=0.9999) over the concentration range of 30-80 µg mL-1. The selectivity 
of the method was proven through degradation studies. The method demonstrated satisfactory results for 
precision, accuracy, limits of detection and quantitation. The robustness of this method was evaluated 
using the Plackett–Burman fractional factorial experimental design with a matrix of 15 experiments and 
the statistical treatment proposed by Youden and Steiner. Finally, the proposed method could be also an 
advantageous option for the analysis of cefazolin sodium, contributing to improve the quality control 
and to assure the therapeutic efficacy.
Uniterms: Cefazolin sodium/determination. High performance liquid chromatography/reverse-phase/
quantitative analysis. Pharmaceutical industry/quality control. Cefalosporine/quality control. Medicines/
quality control.
Um método cromatográfico em fase reversa foi validado para a determinação de cefazolina sódica 
em pó liofilizado, a ser aplicado no controle de qualidade em indústrias farmacêuticas. O método por 
cromatografia líquida foi conduzido em coluna Zorbax Eclipse Plus C18 (250 × 4,6 mm, 5 µm) mantida 
à temperatura ambiente. A fase móvel consistiu de água purificada: acetonitrila (60 : 40 v/v), com o pH 
ajustado para 8 com trietilamina. A vazão usada foi de 0,5 mL min-1 e os analitos de interesse foram 
monitorizados a 270 nm. O tempo de retenção da cefazolina sódica foi de 3,6 min. As áreas dos picos de 
cefazolina sódica foram lineares na faixa de concentração de 30-80 µg mL-1 (r2 = 0,9999). A seletividade do 
método foi demonstrada através de estudos de degradação. O método demonstrou resultados satisfatórios 
para precisão, exatidão, limites de detecção e de quantificação. A robustez do método foi avaliada 
utilizando o esquema fatorial de Plackett-Burman com uma matriz de 15 experimentos simultâneos, 
e analisados por tratamento estatístico proposto por Youden e Steiner. Finalmente, o método proposto 
pode ser também uma opção de êxito para a análise de cefazolina sódica, contribuindo para o controle 
de qualidade e para garantir a eficácia terapêutica.
Unitermos: Cefazolina sódica/determinação. Cromatografia líquida de alta eficiência/fase reversa/
análise quantitativa. Indústria farmacêutica/controle de qualidade. Cefalosporina/controle de qualidade. 
Medicamentos/controle de qualidade.
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INTRODUCTION
Since  thei r  d iscovery  by Brotzu in  1948, 
cephalosporins maintain themselves as a class of 
antimicrobials that stands out for their high therapeutic 
importance and frequency of use, because of their 
safety and very effective use against a large variety 
of microbial agents (Brunton et al., 2012). Cefazolin 
sodium (CFZ) is a β-lactam semi synthetic antibiotic 
classified as a first-generation cephalosporin; it has been 
commercially available since 1970, only in the form 
of pharmaceutical powder for injectable solution, not 
having oral absorption (Bolós et al., 1987). Its use in 
clinical practice is distinguished for being used worldwide 
and keeping more than 40 years as a drug of choice for 
preoperative prophylaxis of various surgical procedures 
(Kusaba, 2009). Considering that it can be administered 
less frequently because of its longer half-life, a single 
dose of cefazolin immediately before surgery is the 
most widely used prophylaxis (Brunton et al., 2012), 
and reduces the incidence of infections that may pose 
serious complications in patients undergoing surgery 
(Wang et al., 2004). Although the antibacterial spectrum 
of cefazolin sodium is the typical of other first-generation 
cephalosporins, it prevails by demonstrating activity 
against Enterobacter, which makes it favorite among 
cephalosporins from this group (Kusaba, 2009; Brunton 
et al., 2012).
High performance liquid chromatography is a 
very common separation technique and broadly used for 
antibiotic quantification. That a large number of methods 
using high performance liquid chromatography is available 
in the literature stems from the numerous advantages that 
the method provides (Salgado et al., 2005; Tozo, Salgado, 
2006; Moreno, Salgado, 2008; Lopes, Salgado, 2009; 
Bonfilio et al., 2009; Cazedey et al., 2011; Corrêa et al., 
2012; Silva, Salgado, 2012). Many methods described for 
CFZ up to the moment are directed to its quantification in 
biological matrices (Wold, 1977; Bayoumi et al., 1986; 
Nahata, 1990; Liang et al., 1994; Bompadre et al., 1998; 
Al-Rawithi et al, 2000; Samer, et al., 2000; Tsai, Chen, 
2000; Arayne et al., 2007; Farthing et al., 2008), requiring 
pretreatment of the sample, among other slow procedures, 
requiring sophisticated equipment and high costs and 
using large amounts of organic solvents which are toxic 
for the operators and for the environment. Few studies 
were validated for quantification of CFZ in pharmaceutical 
form (Moore et al., 1991; Pinto et al., 1995; Farag, 1998; 
Shinde et al., 1998; Lalith et al., 2010), for the control 
of drug quality post-production, to be performed by the 
industry providing security for the user.
Studies focused on the development and refinement 
of analytical methodologies are crucial for optimization of 
laboratory tests carried out in the pharmaceutical industry, 
for adjusting the dosage and thus avoiding toxicity and 
development of resistant microorganisms, to thereby 
ensure the efficacy and safety of the consumer. In this 
context different chromatographic systems were tested 
in order to find favorable conditions to develop a new 
analytical method, for the quantification of CFZ injectable 
solution, capable of ensuring therapeutic efficacy of the 
marketed drug globally.
The validated HPLC method is simple, fast and 
versatile, therefore, it can be employed in routine quality 
control analyses of the pharmaceutical industry, reducing 
the analysis time, reducing the use of solvents due to 
low retention time, reducing residue generated and 
consequently presenting lower costs is which justifies the 
strategy adopted in this study.
MATERIAL AND METHODS
Chemicals
CFZ reference substance (purity 98.2 %) and CFZ 
lyophilized injectable form containing 1000 mg of the 
active component, were kindly donated by the Laboratory 
ABL Antibióticos do Brasil Ltda (Cosmopolis-SP, Brazil). 
The vials did not present excipients.
All solutions and mobile phases used in this assay 
were prepared from ultrapure water obtained from a 
Milli-Q Plus (Millipore, USA). HPLC grade acetonitrile 
used in the preparation of the mobile phase was purchased 
from J.T. Baker (Mexico). All other Chemicals were of 
analytical grade.
Apparatus
The HPLC method was performed on a Waters LC 
system (Waters Corporation, Milford, MA) equipped with 
a Waters 1525 binary pump, a Rheodyne Breeze 7725i 
manual injector and a Waters 2487 UV detector. The peak 
areas were integrated automatically by a computer using 
the Empower software program.
The chromatographic separation was carried out 
under isocratic reversed phase conditions on an Agilent™ 
Zorbax Eclipse Plus C18 (250 x 4.6 mm, 5 µm particle size) 
column.
HPLC Method
The procedure was performed isocratically at room 
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temperature. The mobile phase consisted of purified 
water and acetonitrile with 60:40 v/v, pH adjusted to 8, 
with drops of triethylamine (Merck). The volume of the 
injection was 10 µL at a flow rate of 0.5 mL min-1, using 
UV detection at 270 nm. The solutions were filtered 
through a 0.45 µm filter (Pall Corporation, Michigan, 
USA) before being injected, and the mobile phase was 
degassed by ultrasound bath before being used.
Preparation of standard and sample solutions
A quantity of 10 mg of CFZ were accurately 
weighted and transferred to the 50 mL volumetric flask, 
and the volume was completed with mobile phase in order 
to obtain a stock solution of 200 µg mL-1. Aliquots of this 
solution were transferred to 10 mL volumetric flasks, 
whose volumes were completed with mobile phase, in 
order to obtain the working solutions of 30.0, 40.0, 50.0, 
60.0 and 80.0 µg mL-1, which were used in the assay.
Method validation
The method was validated following the International 
Conference Harmonization (ICH, 2005) guidelines for 
validation of analytical methods.
System Suitability
The system suitability test was conducted to evaluate 
the resolution and reproducibility of the system to ensure 
that the complete testing system was suitable for the 
intended application. In order to obtain the required data, 
six solutions of CFZ reference standard at a concentration 
of 60.0 µg mL-1 were prepared and analyzed by HPLC. 
The parameters such as peak area, retention time (tR), plate 
number (N), tailing factor (TF), and asymmetry factor (AS) 
and their respective relative standard deviation (RSD) 
were analyzed.
Linearity
Linearity was determined by the construction of three 
independent analytical curves. For this, aliquots of the 
stock solution were transferred to other volumetric flasks 
with the same solvent, to obtain six final concentrations: 
30-80 μg mL-1. The results were subjected to regression 
analysis by a least-squares method to calculate the 
calibration equation in which the determination coefficient 
and validity of the statistical parameters were evaluated.
Precision
Precision was assessed at different levels: Repeat-
ability (intra-assay), by testing six evaluations of the same 
concentration sample of CFZ of 60.0 µg mL-1, all on the 
same day and under the same experimental conditions 
and intermediate precision (inter-assay) by conducting the 
analysis on three different standard solution concentrations 
(high, intermediate and low), on three different days under 
the same experimental conditions (inter-days), and also 
by different analysts performing the analysis in the same 
laboratory (between analysts). Precision was evaluated 
by % RSD.
Detection and quantification limits
The LOD and LOQ of CFZ by the proposed method 
were determined using calibration standards. LOD and 
LOQ were calculated as 3 and 10 σ/S, respectively, where 
S is the slope of the calibration curve and σ is the standard 
deviation of y-intercept of regression equation.
Accuracy
Accuracy was attained via the recovery assay, 
in which known quantities of CFZ reference standard 
were added to a known quantity of the sample (ICH, 
2005). The accuracy of the method was evaluated in 
triplicate at three concentration levels (R1 = 80, R2 = 100 
and R3 = 120%), and the percentage recoveries were 
calculated. Standard addition and recovery experiments 
were conducted to determine the accuracy of the method 
for the quantification of CFZ in the drug product. This 
test was carried out by adding known amounts of CFZ-
RS (0.90, 1.50 and 2.10 µg mL-1) to the samples. The 
study was carried out in triplicate. Samples were prepared 
according to Table I.
TABLE I - Determination of the accuracy of the analytical method for the analysis of CFZ by HPLC
CFZ sample
(100 µg mL-1) (mL)
CFZ RS 
(100 µg mL-1)(mL)
Theoretical concentration 
(µg/mL)a
R1 1.5 0.9 48
R2 1.5 1.5 60
R3 1.5 2.1 72
a10 mL volumetric flask
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The percentage of recovered cefazolin sodium was 
calculated by equation 1.
  (1)
where: CA= concentration of the sample solution found 
added to RS (µg mL-1); CS= concentration found in the 
sample (µg mL-1); CT= theoretical concentration of the 
solution added RS (µg mL-1).
Selectivity and study of forced degradation
The selectivity of the method was determined 
by subjecting a CFZ sample solution (200 µg mL-1) to 
accelerated degradation by acidic, basic, neutral and 
photolytic conditions. The samples were evaluated 
at a concentration of 60 µg mL -1. The sample was 
degraded in solutions of 0.001 mol L-1 HCl, 0.1 mol L-1 
NaOH, and in purified water by acid, basic and neutral 
hydrolysis respectively, all maintained at 60 °C for 48 h. 
Photodegradation was induced by exposing the samples in 
a photostability chamber to 200 W h/m2 of near UV light 
for 48 h. After the procedures, the samples were diluted 
with the mobile phase and were injected in the HPLC at a 
concentration of 60 µg mL-1.
Robustness
The robustness of the method was demonstrated by 
the Plackett–Burman design, to evaluate the reliability of 
the analysis concerning small variations in its working 
parameters. Table II shows the factorial combination 
used in the Plackett-Burman test, where the letters A-G 
represent the parameters selected; 1-15 is the factors 
changed, where the level (0) is the optimal values of the 
procedure, whereas levels (1) and (−1) are respectively 
upper and lower values with regard to the selected 
one (0).
The choice of variables (factors) and levels that 
must be tested is very important to obtain a reliable test of 
robustness. The variables must be consistent with reality 
and practice levels should reflect the variation that can be 
generally observed. The factors and varying levels tested 
are shown in Table III.
TABLE III - Selected Factors and levels of variability
Factors Unit Limit Condition varied (-1)
Condition Normal 
(0)
Condition varied 
(1)
A. Column brand ----- ----- Waters Agilent Waters
B. Mobile phase flow rate mL/min ± 2 0.48 0.5 0.52
C. Acetonitrile brand ----- ----- Tedia J. T. Baker Tedia
D. Proportion of FM % ± 2 58:42 v/v 60:40 v/v 62:38 v/v
E. Volume of injection µL ± 2 8 10 12
F. Wavelength λ ± 2 268 nm 270 nm 272 nm
G. Room temperature °C ± 2 23 25 27
-1= Lower level; 0= Normal Level and +1 Upper Level.
TABLE II - Robustness test using the experimental model of Plackett-Burman
Parameter 
analytical
Combination factorial
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
A 1 1 1 0 1 0 0 0 -1 -1 -1 0 -1 0 0
B 0 1 1 1 0 1 0 0 0 -1 -1 -1 0 -1 0
C 0 0 1 1 1 0 1 0 0 0 -1 -1 -1 0 -1
D 1 0 0 1 1 1 0 0 -1 0 0 -1 -1 -1 0
E 0 1 0 0 1 1 1 0 0 -1 0 0 -1 -1 -1
F 1 0 1 0 0 1 1 0 -1 0 -1 0 0 -1 -1
G 1 1 0 1 0 0 1 0 -1 -1 0 -1 0 0 -1
A–G: selected factors; 1–15: N (number of experiments) = 2n + 1 where n = number of factors; −1, 0, +1: levels for the factors
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The robustness was determined in triplicate from 
injections of standard solutions containing 60 µg mL-1 
CFZ, under the same established experimental conditions.
To determine the influence of changes in each 
parameter on the final result, the average of dosage 
performed in triplicate assay corresponding to normal 
ranges was compared to the average of dosage corresponding 
to the modified levels.
The average effect of each variable is the average 
difference among the observations made at the modified 
levels and those made at the optimum level. The deviation 
of each factor was calculated using the methodology 
Youden and Steiner.
Equation 2 illustrates the effect evaluation of the 
changing parameter A-brand column, likewise the other 
parameters were also evaluated (Berzas et al., 2004).
   (2)
where:
  
Since the deviation of each factor changed (DA, DB, 
DC etc) should be less than the value resulting from √2S 
to infer that the effects obtained with the variations of the 
parameters were not significant and therefore the method 
is robust for all selected factors.
RESULTS AND DISCUSSION
Preliminary tests were carried out in order to 
obtain a reliable method so as to avoid damage to 
the chromatographic column and try to decrease 
formation of residue. Many mobile phase systems 
were tested in different chromatographic columns. 
Still to establish the best working conditions, the 
distribution coefficient (log D) was determined using 
ACD/Labs 6.0 software, considering that the distribution 
coefficient is the evaluation of the partition coefficient 
(log P) at different pHs. The results indicate that the 
pH where the drug solubility is more stable is between 
7 and 11 (Figure 1). However this chromatographic column 
can be used over a pH range of 2-9. Therefore, the pH range 
from 7 to 9 is indicating to perform the analysis. The mobile 
phase was adjusted to pH 8 using drops of triethylamine.
The CFZ chromatogram obtained by the proposed 
method showed good resolution and peak symmetry. 
The retention time observed (3.6 min) allows a rapid 
determination of the CFZ, which is desirable for a routine 
analysis (Figure 2).
FIGURE 1 - CFZ distribution coefficient determined by ACD/
Labs 6.0 software.
System suitability
The results of system suitability indicate that the 
selected chromatographic parameters are able to identify 
and quantify the drug analyzed. The results are consistent 
with the literature (FDA, 2004). The system suitability 
was checked by injecting six replicate solutions of CFZ 
RS in with concentration of 60 µg mL-1. The parameters 
measured in system suitability were peak area, retention 
time, resolution, peak purity, tailing factor, capacity factor 
and theoretical plate. In all measurements the peak area 
FIGURE 2 - Chromatogram of CFZ (60 µg mL-1). Chromatogram 
standard - black, sample – blue.
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varied less than 2.0%, the average retention time was 
3.6 minutes (Relative Standard Deviation = 0.16%), the 
retention factor was more than 2, plate number was more 
than 7803 and tailing factor was less than 2, for the CFZ 
peak. The proposed method offers good detectivity and 
CFZ can be detected accurately. The results obtained for the 
parameters of System Suitability are presented in Table IV.
Linearity
Table V shows the values of areas obtained by the 
different concentrations of CFZ RS.
Residue analysis indicated that the regression model 
used is appropriate. Each average value of absolute areas 
obtained in determining the analytical curve was plotted 
in relation to its concentration, observing linearity in the 
range of 30-80 µg mL-1, as shown in Figure 3.
The results for linearity were statistically analyzed 
using tests of variance (ANOVA); according to ANOVA 
there is no deviation from linearity in calibration curve 
and the regression model is appropriate. The ANOVA 
calculated for the data from the analytical curve of CFZ 
is presented in Table VI.
Precision
The precision of the method was determined by 
repeatability (intraday), expressing the results based 
on the RSD. Seven solutions of CFZ were prepared in 
a concentration of 60 µg mL-1 and were submitted to 
successive analyses and the date obtained on the same 
day under the same experimental conditions, by the same 
analyst and at the same laboratory, providing a RSD 
of 0.84%. For the determination of interday precision, 
analyzes were performed using three samples, on three 
consecutive days, yielding experimental values of contents 
of 100.29% 100.11% to 100.79%, with an average content 
of 100.39% and RSD was 0.35%. For precision between 
analysts, two samples were evaluated by two analysts, 
obtaining experimental values of 98.49% and 100.12%, 
with an average of 99.31% and RSD of 1.17, as shown in 
Table VII.
The precision showed RSD values lower than 
TABLE IV - Parameters evaluated in system suitability test
Parameters evaluated
Asymmetry 
(≤ 2.0)
Tailing Factor 
(≤ 2.0)
Capacity Factor 
(> 2.0)
Plate numbers 
(>2000)
Retention Time 
(min) Area
1.0 0.36 2.27 7803.61 3.603 4063634
1.0 0.36 2.27 7833.96 3.610 4094335
1.0 0.36 2.27 7838.30 3.611 4077877
1.0 0.36 2.27 7868.73 3.618 4097063
1.0 0.38 2.27 7807.94 3.604 4090641
1.0 0.36 2.27 7855.68 3.615 4085460
average 1.0 0.36 1.0 7834.70 3.61 4084835
aRSD 0.0 1.69 0.0 0.33 0.16 0.30
aRSD= Relative standard deviation
TABLE V - Values of the peak areas for the CFZ RS to the 
analytical curve
Concentration 
(µg mL-1)
Areasa 
(AU)
Average 
Area 
RSDb
(%)
30 2152162
2107217 2110833 1.87
2073120
40 2764639
2756486 2752218 0.55
2735528
50 3349823
3380328 3372399 0.58
3387046
60 3971999
3912803 3969727 1.40
4024378
70 4572851
4513790 4589643 1.86
4682288
80 5154763
5136111 5183200 1.27
5258725
a Average value of three determinations / bRSD = Relative 
standard deviation
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FIGURE 3- Residue analysis and analytical curve for CFZ RS obtained by chromatographic method, using purified water: acetonitrile 
(60:40 v/v) pH 8 adjusted with TEA, as mobile phase. Stationary Phase: Agilent Zorbax Eclipse Plus C18 (250 x 4.6 mm, 5 µm).
TABLE VI - Analysis of variance (ANOVA) for linearity
Source of variation Degree of freedom Sum of squares Variability F calculated F critical
Between concentration 5 19760858787504.8 3952171757500.9 1396.43* 3.11
Linear regression 1 19760858787504.8 19760858787504.8 6982.14* 4.75
Deviation of linearity 4 0.00003 0.0000075 0.00 3.26
Residue 12 33962392533.3 2830199377.7 - -
Total 17 19794821180038.2 - - -
* Significant at p <0.05 %
TABLE VII - Results for cefazolin sodium method precision
Interday precision Between-analysts precision
Day Contenta 
(%)
Average 
Content (%)
RSDb 
(%)
Analist Contenta 
(%)
Average 
Content (%)
RSDb 
(%)
1 100.29 100.39 0.35 A 100.12 99.31 1.17
2 100.11 B 98.49
3 100.79
aaverage of three determinations; bRSD= relative standard deviation
recommended in the literature (ICH, 2005; FDA, 2004). 
The results obtained in interday precision and precision 
between-analyst were also statistically evaluated by 
analysis of variance and according to ANOVA there 
was no significant deviation, as shown in Table VIII and 
Table IX.
TABLE VIII - Analysis of variance (ANOVA) for interday precision
Source of variation DF Sum of squares Average squares F calculated P-value F critical
Between groups 2 269208531.8 134604265.9 0.10 0.89 3.55
Within groups 18 22465779885 1248098882
Total 20 22734988417
* p > 0.05%
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Accuracy
The accuracy showed good recovery between the 
true value and the value found. The accuracy of the method 
was determined by analysis of three concentrations 
in the pre-established range and experimental results 
corresponding to the average percentage of 100.37% are 
shown in Table X. 
Limits of detection and quantification
The sensitivity of the method was determined 
by chromatographic detection (LOD) and quantitation 
(LOQ) limits. The value calculated for the lowest 
concentration detected by analytical procedure was 
3.10 µg mL-1. In turn, the calculated LQ was 9.41 µg mL-1. 
The calculated values for the LOD and LOQ indicated 
the ability of the method to detect and quantify reliably 
CFZ.
Selectivity
Selectivity of the method was evaluated by forced 
degradation observing the chromatograms of the cefazolin 
sodium standard containing possible degradation 
products. The chromatograms depicted in Figure 4 show 
that the degradation products had negligible effect on to 
the cefazolin sodium peak. However in degradations in 
neutral or photolytic conditions showed no additional 
peaks, but showed a significant decrease of 62% and 
68%, respectively, compared to the peak of drug at the 
time of preparation. Moreover, the resolution among 
cefazolin sodium and potential degradation products 
was higher than 1.5 indicating adequate separation of 
cefazolin sodium from other peaks (Snyder et al., 2010). 
This separation confirmed the method selectivity for 
degradation products.
Robustness
The robustness was evaluated by the Plackett-
Burman factorial matrix, in which 15 experiments 
were performed with simultaneous changes, previously 
presented in Table II and Table III. The effects resulting 
from the changed parameters have been evaluated in 
comparison to the values obtained as reference for the test 
+1 1.47 and 1.54 for the test -1 (Equation 2). No effect 
showed significant results, indicating that the proposed 
method is robust. The robustness was confirmed by the 
Plackett-Burman model. The results indicated that the 
validity of the method is maintained even with small 
variations in its working conditions. Concentrations found 
in normal conditions and changed for each factor are 
shown in Table XI.
The results of method validation for the analysis of 
CFZ showed that the developed high performance liquid 
chromatography method is appropriate to quantify this 
cephalosporin in powder for injection.
CONCLUSION
The present study involves development of HPLC 
method using simple mobile phase which contains no 
buffer in its constitution, which is sensitive and rapid, 
as well as subsequent validation of developed method 
according to ICH guidelines. Prioritizing shorter analysis 
can reduce the consumption of organic solvents making 
the method financially advantageous for quantification 
TABLE IX - Analysis of variance (ANOVA) for between-analyst precision 
Source of variation DF Sum of squares Average squares F calculated P-value F critical
Between groups 1 718684.57 718684.57 0.00026 0.98 4.74
Within groups 12 32952861485 2746071790
Total 13 32953580170
* p > 0.05%
TABLE X- Results for cefazolin sodium method accuracy
CFZ RS added 
(µg mL-1)
CFZ RS founda 
(µg mL-1)
Recuperation 
(%)
Average recuperation 
(%) RSD
b (%)
R1 18 18.21 101.16 100.37
R2 30 30.16 100.52 0.86
R3 42 41.76 99.44
aaverage of three determinations; bRSD= relative standard deviation
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of CFZ in pharmaceutical powder in the pharmaceutical 
industry. The method proved to be able to quantify the 
cefazolin sodium in its pharmaceutical form, fulfilling 
the necessary criteria such as system suitability and 
validation of system, as linearity, precision, accuracy 
and robustness. The method is financially advantageous 
for the pharmaceutical industry, because the analysis 
is fast, and it generates a smaller amount of organic 
solvent waste. Thus this method is indicated for be used 
in routine quality control analyses of the pharmaceutical 
industry.
ACKNOWLEDGEMENTS
The authors wish to thank the pharmaceutical 
company ABL - Antibióticos Brazil Ltda (Brazil) for the 
supply of the samples and thank the FAPESP, CNPq and 
PADC – UNESP for financial support.
TABLE XI - Results for cefazolin sodium method robustness
Factor (+1) Content (%)a,b (-1) Content (%)a,b
Column brand A= Waters™ 100.38–101.46= -1.08 A= Waters™ 100.83 – 101.63 = -0.80
Mobile phase flow rate (µg mL-1) B= 0.52 101.21–100.63= 0.58 B= 0.48 101.30 – 101.15 = 0.15
Acetonitrile brand C= Tedia 100.89–100.95= -0.06 C= Tedia 100.71 – 101.75 = -1.04
Proportion of FM (%) D= 62:38 101.00–100.83= 0.17 D= 58:42 101.19 – 101.27 = -0.08
Volume of injection (mL) E= 12 100.92–100.92= 0.00 E= 8 100.85 – 101.60 = -0.75
Wavelength (nm) F= 272 100.71–101.13= -0.42 F= 268 101.52 – 100.94 = 0.58
Room temperature (°C) G= 27 101.70–101.14= -0.56 G= 23 101.25 – 101.20 = 0.05
aAverage contents obtained in normal conditions - Average contents obtained in the altered conditions; bReference criteria calculated: 
1.47 (Test +1) and 1.54 (Test-1)
FIGURE 4 - CFZ Chromatogram of 60 µg mL-1 before degradation (a) and after 48 hours under degradation (b). In Basic (0.1 mol L-1 
NaOH) at 60 °C (A); acid (0.001 mol L-1 HCl) at 60 °C (B) neutral (purified water) at 60 °C (C); and photolytic (UV) at room 
temperature (D).
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